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Abstract
Purpose Although thyroid hormones are irrefutably implicated in cardiovascular physiology, the impact of within-reference
range variations of thyroid function on cardiovascular disease (CVD) remains unclear. Elucidating this is important, since it
could foster preventive treatment and reduce global CVD burden. We therefore investigated the impact of within-reference
range variations of thyroid function on all-cause and cardiovascular mortality.
Methods We included community-dwelling individuals aged 28–75 years from a prospective cohort study, without known
use of thyroid-affecting therapy and with thyrotropin within reference range. Associations of thyroid function with mortality
were quantified using Cox models and adjusted for sociodemographic and cardiovascular risk factors.
Results Mean (SD) age of the 6,054 participants (52.0% male) was 53.3 (12.0) years. During 47,594 person-years of follow-
up, we observed 380 deaths from all causes and 103 from CVDs. Although higher thyrotropin was not associated with all-
cause mortality (adjusted HR 1.02, 95% CI 0.92–1.14), point estimates for cardiovascular mortality diverged toward
increased risk in younger (<72 years) participants (1.31, 1.00–1.72) and decreased risk in elderly (≥72 years) (0.77,
0.56–1.06). Higher free thyroxine (FT4) was associated with all-cause mortality (1.18, 1.07–1.30) and with cardiovascular
mortality only in elderly (1.61, 1.19–2.18), but not in younger participants (1.03, 0.78–1.34). Higher free triiodothyronine
(FT3) was associated with all-cause mortality in females only (1.18, 1.02–1.35). FT3 was not associated with cardiovascular
mortality (0.91, 0.70–1.18).
Conclusions Community-dwelling elderly individuals with high-normal thyroid function are at increased risk of all-cause
and cardiovascular mortality, reinforcing the need of redefining the current reference ranges of thyroid function.
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Introduction
Abnormal thyroid function represents a significant public
health burden, with an estimated prevalence approaching 70
per 1,000 individuals [1]. The potential health consequences
are devastating if left untreated [2, 3]. Clinical (overt)
thyroid dysfunction is defined as thyrotropin and free
thyroxine (FT4) outside the reference ranges, whereas hav-
ing abnormal thyrotropin with normal FT4 is referred to as
subclinical thyroid dysfunction. To date, the 2.5th and
97.5th percentiles of the distribution of thyroid hormones,
garnered from an apparently healthy population, serve as
the mainstay in the establishment of the reference ranges
[4]. Recent studies, however, have instigated the debate as
to whether this approach has need of revision when risks for
clinical outcomes are pondered as well [5–8].
Cardiovascular diseases (CVDs), currently the prime
cause of death in developed countries, represent such an
outcome. Although a large proportion of CVD events is
explained by established risk factors, an estimated 25% still
remains elusive [9]. As thyroid hormones are critically
implicated in the cardiovascular system [10], special
attention was drawn to thyroid hormones as potential bio-
markers capable of explaining this remnant risk. Indeed,
abnormal thyroid function, either clinical or subclinical, is a
well-recognized risk factor of CVD [11–15]. Whether this
risk extends into the established reference ranges remains to
be determined [5–8, 14, 16, 17], and this information is
important since it could pave the way for potential pre-
ventive treatment, and hence reduce the global disease
burden inflicted by CVDs.
The aim of this study was therefore to investigate the
impact of variations within reference ranges of thyroid
function on all-cause and cardiovascular mortality in
community-dwelling participants from the general
population-based Prevention of REnal and Vascular ENd-
stage Disease (PREVEND) Study.
Methods
Study design and participants
The PREVEND study investigates the risk factors for and
the prevalence and consequences of microalbuminuria in
otherwise healthy adults in the city of Groningen (The
Netherlands). This cohort is specifically designed to moni-
tor the long-term development of cardiac, renal, and per-
ipheral vascular end-stage disease. The objectives and
design have been described in detail elsewhere [18]. Briefly,
all 85,421 inhabitants of the city of Groningen aged 28–75
years were invited, from 1997 to 1998, to participate in the
study and were asked to complete a brief questionnaire and
provide morning urine. The urinary albumin excretion
(UAE) was determined in 40,856 responders. Pregnant
women and participants with insulin-dependent diabetes
mellitus were excluded. Participants with a UAE ≥ 10 mg/L
(n= 7,768) were requested to participate in the cohort, of
whom 6,000 were enrolled. In addition, a randomly chosen
control group with a UAE of <10 mg/L (n= 3,395) was
invited, of whom 2,592 were enrolled. These 8,592 parti-
cipants constitute the PREVEND cohort. A second
screening round took place from 2001 to 2003, encom-
passing 6,894 participants and was considered the “base-
line” for the current study. Detailed information on the flow
of participants through the study is provided in Fig. 1. We
included 6,054 participants who fulfilled the inclusion cri-
teria of not using thyroid hormone replacement or thyroid-
affecting therapy (including levothyroxine, liothyronine,
carbimazole, propylthiouracil, thiamazole, lithium salts, and
amiodarone), having thyrotropin within the reference range
of 0.27–4.20 mIU/L, and follow-up data on all-cause and
cardiovascular mortality. The PREVEND study has been
approved by the medical ethics committee of the University
Medical Center Groningen and was undertaken in accor-
dance with the Declaration of Helsinki. All participants
provided written informed consent.
Procedures
Each screening comprised two visits to an outpatient clinic
separated by three weeks. Self-administered questionnaires
concerning demographics, cardiovascular and renal disease
history, smoking habits, and medication use were provided
by all participants prior to the first visit. Information on
medication use was combined with information from IADB.
nl, a data base containing information of prescribed medi-
cation in public pharmacies in The Netherlands (http://www.
iadb.nl/). Thyrotropin, thyroid function measurements, and
antithyroid peroxidase were performed in baseline fasting
serum samples stockpiled at −80 °C using the Roche
Modular E170 Analyzer electrochemiluminescent immu-
noassays (Roche Diagnostics, Mannheim, Germany). Sam-
ples had been stored between 14 and 17 years and had not
been thawed before. The expected values for thyrotropin
(0.27–4.20 mIU/L), FT4 (12–22 pmol/L), and FT3
(3.1–6.8 pmol/L) as supplied by the manufacturer were set
as the reference ranges. An antithyroid peroxidase titer of
>34 kIU/L was considered positive.
Outcomes
Study outcomes were incidence of all-cause mortality and
cardiovascular mortality. Qualifying cardiovascular events
comprised the International Classification of Diseases
(ICD)-10 codes I10-I90. Data on mortality were obtained
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from municipality records and the cause of death was
obtained from and classified by a physician from Statistics
Netherlands and coded according to the 10th revision of
the ICD.
Statistical analyses
Survival time was calculated as the period between the
second screening round (baseline) and events defined as
death, loss to follow-up, or the end of the follow-up period
(January 1, 2011), whichever came first. If a person had
moved to an unknown destination, the date on which the
person was dropped from the municipal registry was used as
the census date. Linear trends across sex-stratified quartiles
were determined using analysis of variance for normally
distributed data, the Jonckheere–Terpstra test for skewed
data, and the Mantel–Haenszel test of trend for categorical
data. Crude linear associations between thyrotropin, FT4,
and FT3 in all individuals and in younger (≤72 years) and
elderly (>72 years) individuals separately were quantified
by determining Pearson product–moment correlation coef-
ficients. The rationale for this age cutoff is discussed below.
We used Cox proportional hazards models to compute
hazard ratios (HRs) of the association of thyrotropin, FT4,
and FT3 with all-cause and cardiovascular mortality. Prior
to entering the model, the correct covariate functional forms
of thyrotropin, FT4, and FT3 were graphically determined
by fitting a smoothing spline to the martingale residuals,
obtained from a single Cox model fitting all covariates but
thyrotropin, FT4, or FT3, along with a least squares multi-
variable regression line with thyrotropin, FT4, or FT3 as the
dependent variable and all other covariates as independent
variables [19]. The proportional hazards assumption was
verified visually with plots of the scaled Schoenfeld resi-
duals and formally by the Grambsch–Therneau goodness-
of-fit test. All analyses were adjusted for the baseline values
of all potential confounding variables (age, sex, current
smoking, body-mass index, systolic blood pressure, use of
Fig. 1 Flow of the participants
through the study. *Size of the
random sample was arbitrarily
set at 3,395 (out of the 22,350
eligible participants) to obtain a
total cohort size of ~10,000,
taking into account a 15%
nonparticipation rate
Endocrine
antihypertensive and lipid-lowering medications, total cho-
lesterol/high-density lipoprotein cholesterol ratio, triglycer-
ides, type 2 diabetes, C-reactive protein, history of CVD,
estimated glomerular filtration rate, and UAE) as fixed
effects, which were selected on the basis of biological
plausibility and previous literature. Point estimates are
Table 1 Baseline characteristics of the 6,054 participants according to sex-stratified quartiles of FT4
Sex-stratified quartiles of FT4
I II III IV
Ptrend
Male <14.5 14.5–15.8 15.9–17.2 >17.2
Female <14.1 14.1–15.4 15.5–16.7 >16.7
All participants
(N= 6,054)
Male 788 787 787 787
FT4, pmol/L Female 727 726 726 726
Sociodemographic characteristics
Age 53.3 (12.0) 54.0 (11.4) 53.5 (11.6) 52.7 (12.1) 52.9 (12.6) 0.002
Race
Caucasian 5766 (95.2) 1452 (95.8) 1445 (95.5) 1439 (95.1) 1430 (94.5) 0.02
Negroid 60 (1.0) 18 (1.2) 18 (1.2) 13 (0.9) 11 (0.7)
Asian 116 (1.9) 19 (1.3) 28 (1.9) 36 (2.4) 33 (2.2)
Other 66 (1.1) 14 (0.9) 14 (0.9) 17 (1.1) 21 (1.4)
Unknown 46 (0.8) 12 (0.8) 8 (0.5) 8 (0.5) 18 (1.2)
Education
Low 2612 (43.1) 693 (45.7) 677 (44.7) 638 (42.3) 604 (39.9) 0.001
Middle 1543 (25.5) 385 (25.4) 360 (23.8) 388 (25.6) 410 (27.1)
High 1899 (31.4) 437 (28.8) 476 (31.5) 487 (32.2) 499 (33.0)
Current smoking 1749 (28.9) 385 (25.4) 416 (27.5) 464 (30.7) 484 (32.0) <0.001
Drinking alcohol, ≥10 g/day 1638 (27.1) 404 (26.7) 414 (27.4) 419 (27.7) 401 (26.5) 0.98
Type 2 diabetes 363 (6.0) 94 (6.2) 106 (7.0) 83 (5.5) 80 (5.3) 0.12
History of CVD 389 (6.4) 80 (5.3) 107 (7.1) 113 (7.5) 89 (5.9) 0.43
Thyroid function
TSH, mIU/L 1.72 (0.82) 1.89 (0.87) 1.75 (0.83) 1.68 (0.78) 1.57 (0.75) <0.001
FT3, pmol/L 4.8 (4.5–5.2) 4.7 (4.3–5.0) 4.8 (4.5–5.1) 4.9 (4.6–5.2) 5.0 (4.7–5.4) <0.001
Anti-TPO, kIU/L 10.3 (8.1–13.8) 10.2 (8.0–13.9) 10.3 (7.9–13.5) 10.3 (8.1–13.7) 10.5 (8.3–14.1) 0.09
Body composition
BMI, kg/m2 26.6 (4.3) 27.3 (4.5) 26.7 (4.3) 26.5 (4.3) 26.1 (4.1) <0.001
Haemodynamics
SBP, mmHg 126.2 (18.7) 126.2 (18.4) 125.9 (18.3) 126.1 (18.9) 126.5 (19.2) 0.62
DBP, mmHg 73.5 (9.2) 73.6 (9.4) 73.7 (9.1) 73.4 (9.1) 73.2 (9.1) 0.22
Lipid spectrum
Total cholesterol, mmol/L 5.4 (1.0) 5.5 (1.1) 5.4 (1.0) 5.4 (1.0) 5.4 (1.1) <0.001
HDL cholesterol, mmol/L 1.25 (0.31) 1.24 (0.32) 1.25 (0.31) 1.25 (0.31) 1.26 (0.30) 0.09
Total cholesterol/HDL 4.6 (1.3) 4.7 (1.4) 4.6 (1.3) 4.5 (1.3) 4.5 (1.3) <0.001
Triglycerides, mmol/L 1.12 (0.81–1.61) 1.19 (0.83–1.71) 1.13 (0.81–1.67) 1.10 (0.80–1.56) 1.06 (0.79–1.50) <0.001
Inflammation
Hs-CRP, mg/L 1.36 (0.62–3.11) 1.46 (0.67–3.25) 1.30 (0.61–3.08) 1.41 (0.63–3.14) 1.26 (0.56–3.00) 0.01
Kidney function parameters
eGFRSCr-CysC, mL/min/1.73 m
2 90.8 (20.7) 91.2 (20.7) 91.3 (20.7) 91.2 (21.0) 89.5 (20.6) 0.02
UAE, mg/day 8.7 (6.1–15.8) 8.9 (6.1–17.2) 8.7 (6.0–15.6) 8.8 (6.1–15.3) 8.3 (6.0–15.6) 0.05
UAE categories
<15 mg/day 4436 (73.3) 1080 (71.3) 1114 (73.6) 1126 (74.4) 1116 (73.8) 0.10
15–29.9 mg/day 818 (13.5) 206 (13.6) 217 (14.3) 201 (13.3) 194 (12.8)
30–300 mg/day 707 (11.7) 199 (13.1) 166 (11.0) 160 (10.6) 182 (12.0)
>300 mg/day 93 (1.5) 30 (2.0) 16 (1.1) 26 (1.7) 21 (1.4)
Medication
Antihypertensive drugs 1264 (20.9) 291 (19.2) 297 (19.6) 325 (21.5) 351 (23.2) 0.003
Lipid-lowering drugs 560 (9.3) 146 (9.6) 148 (9.8) 140 (9.3) 126 (8.3) 0.18
Data are mean (SD), median (IQR), or n (%)
BMI body-mass index, CVD cardiovascular disease, CysC serum cystatin C, DBP diastolic blood pressure, eGFR estimated glomerular filtration
rate, FT3 triiodothyronine, FT4 free thyroxine, HDL high-density lipoprotein, Hs-CRP high-sensitive C-reactive protein, SBP systolic blood
pressure, SCr serum creatinine, TPO thyroid peroxidase, TSH thyrotropin, UAE urinary albumin concentration
Endocrine
shown per SD increment in the predictor. Potential mod-
ification of the effect of thyrotropin or thyroid function on
the risk of an event by age and sex was explored by
including product terms in the model, which were allowed a
permissive significance threshold of α= 0.10 [20]. Asso-
ciations in the total population are shown along with sex-
specific prospective associations. In addition, results of age-
stratified associations are given to permit comparison with
findings from previous studies, as they have primarily been
conducted in elderly [5–7, 14, 16]. Cutoff values for the age
strata were established through dichotomization of the
cohort by the median age in participants who had suc-
cumbed to all-cause (70 years) and CVD (72 years), to
obtain an equal number of events per stratum. The lower
and higher age strata are referred to as “younger partici-
pants” and “elderly”, respectively. Only the results of the
full models are reported (multivariable model). Multiple
imputation using fully conditional specification was per-
formed to obtain 20 imputed data sets with five iterations in
the Gibbs sampler per data set [21], in which Rubin’s rules
were applied to acquire pooled estimates of the regression
coefficients and their standard errors across the imputed
data sets [22]. All covariates had <5% missing values
except for C-reactive protein (Supplementary Table 1).
Statistical analyses were performed with R version 3.5.2
(Vienna, Austria) (http://cran.r-project.org/). A two-sided
P value < 0.05 was judged significant.
Sensitivity analyses
We conducted six distinct sensitivity analyses to evaluate
the robustness of the findings. First, to account for potential
bias caused by underlying autoimmune thyroid disease, we
excluded 512 (8.3%) participants with a positive antithyroid
peroxidase titer. Second, any potential bias caused by
abnormal thyroid hormone tests was accounted for by
excluding 221 (3.6%) participants with FT4 and/or FT3
concentrations outside the reference ranges. Third, to
account for any potential bias caused by presence of cancer,
we excluded 276 (4.5%) participants with prevalent
malignancy since the first screening. Fourth, potential
influence of pre-existing CVD on the associations was
accounted for by excluding 389 (6.4%) participants with
CVD at baseline. Fifth, to reduce the potential influence that
preclinical frailty could have on the results (reverse caus-
ality), 51 (13.4%) deaths from all-causes and 20 (19.4%)
from CVD that occurred during the first two years of
follow-up were excluded. Last, to assess the impact of the
cutoff values for the age strata in participants who had
succumbed to all-cause (70 years) and CVD (72 years) on
the obtained results, analyses were conducted with 65 years
of age as the cutoff value for both the endpoint of all-cause
mortality and cardiovascular mortality.
Results
Baseline characteristics
The mean (SD) age of the 6,054 participants was 53.3
(12.0) years of whom 3,149 (52.0%) were male. FT4
concentrations were substantially higher in males than
females (P < 0.001), for which reason the baseline socio-
demographic, clinical, and laboratory characteristics of the
study participants are provided according to sex-stratified
quartiles of FT4 (Table 1). Participants with higher FT4
concentrations were more likely to be younger or currently
smoking, to have enjoyed higher education, to have a
lower body-mass index, total cholesterol, total cholesterol/
high-density lipoprotein cholesterol ratio, triglycerides, C-
reactive protein, kidney function, and to be using anti-
hypertensive drugs. Higher FT4 concentrations were not
associated with a higher prevalence of CVD. Baseline
concentrations of thyrotropin were negatively correlated
with FT4 and FT3, while a positive correlation between
FT4 and FT3 was observed; estimated correlation para-
meters ρ (95% CI) amounted to −0.16 (−0.18 to −0.13),
–0.05 (−0.08 to −0.03), and 0.23 (0.20–0.25), respec-
tively (Supplementary Table 2). In younger individuals,
the correlation between FT4 and FT3 was particularly
strong, with a value of 0.25 (0.22 to 0.27), while in elderly
individuals the correlation between TSH and FT4 was
particularly strong, with a value of −0.22 (−0.30 to
−0.14), while the correlation between FT4 and FT3 was
much weaker, with a value of 0.09 (0.00–0.17). After a
median follow-up of 8.2 (interquartile range, 7.7–8.8)
years, we observed 380 deaths from all causes, 103 of
which were due to CVD.
Association of thyrotropin and thyroid function with
all-cause mortality
Of the 380 deaths, 288 (75.8%) occurred in males and 92
(24.2%) in females. The association of thyrotropin with all-
cause mortality was not statistically significant (HR 1.02,
95% CI 0.92–1.14; P= 0.65) and was neither modified by
sex (Table 2) nor age (Table 3). Higher FT4 was associated
with increased risk of all-cause mortality (1.18, 1.07–1.30;
P= 0.001). This association was more pronounced in
females (1.47, 1.19–1.82; P < 0.001) than in males (1.14,
1.01–1.27; P= 0.03) (Pinteraction= 0.01). Moreover, higher
FT4 was strongly associated with increased risk of all-cause
mortality in elderly (≥70 years) (1.28, 1.11–1.48; P=
0.001) (Table 3). Although FT3 was not associated with all-
cause mortality in the total population (Table 2), a strong
effect modification by sex was observed (Pinteraction=
0.006). Higher FT3 was associated with an increased risk of
all-cause mortality in females (1.19, 1.06–1.34; P= 0.004),
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but not in males (0.92, 0.79–1.07; P= 0.26). This asso-
ciation was not modified by age (Table 3).
All sensitivity analyses yielded similar results for asso-
ciations of thyrotropin and FT4 with mortality (Supple-
mentary Tables 3–13). Exclusion of participants with a
positive antithyroid peroxidase titer, circulating FT4 and/or
FT3 outside the reference ranges, or with prevalent malig-
nancy since the first screening obliterated the association of
higher FT3 with all-cause mortality in females (Supple-
mentary Tables 3, 5, and 7). Other sensitivity analyses on
the associations of thyrotropin and thyroid function para-
meters with mortality provided similar results (Supple-
mentary Tables 3–13).
Association of thyrotropin and thyroid function
parameters with cardiovascular mortality
Of the 103 deaths due to CVD, 83 (80.6%) occurred in
males and 20 (19.4%) in females. No association was
found between thyrotropin and cardiovascular mortality in
the total population (HR 0.98, 95% CI 0.80–1.20; P=
0.86) and this association was not modified by sex (Table
2). Interestingly, opposite effects were observed between
age strata (Pinteraction= 0.04). Higher thyrotropin showed a
trend toward increased risk of cardiovascular mortality in
younger (<72 years) participants (1.31, 1.00–1.72; P=
0.05), whereas an opposite trend was observed in elderly
(≥72 years) (0.77, 0.56–1.06; P= 0.11) (Table 3 and Fig.
2a, b). Higher FT4 was associated with increased risk of
cardiovascular mortality in the total population (1.23,
1.02–1.49; P= 0.03), without effect modification by sex
(Table 2). A strong association of higher FT4 with
increased risk of cardiovascular mortality was observed in
elderly (1.61, 1.19–2.18; P= 0.002) (Fig. 2c, d). This
association was absent in younger participants (1.03,
0.78–1.34; P= 0.85) (Table 3). No association between
FT3 and cardiovascular mortality was detected (0.91,
0.70–1.18; P= 0.48), and risk estimates neither differed
between sexes (Table 2) nor between age strata (Table 3).
Sensitivity analyses showed that exclusion of partici-
pants who developed malignancy since the previous
screening further increased the effects of thyrotropin in the
younger (<72 years) participants (1.34, 1.02–1.77; P=
0.04) and elderly (≥72 years) (0.68, 0.48–0.97; P= 0.03)
(Supplementary Table 8). The exclusion of participants with
preexisting CVD at baseline reinforced the association of
higher FT4 and cardiovascular mortality in elderly (≥72
years) (1.73, 1.16–2.57; P= 0.007) (Supplementary Table
10). Other sensitivity analyses on the associations between
thyrotropin and thyroid function parameters with cardio-
vascular mortality provided similar results (Supplementary
Tables 3–13).
Discussion
In this analysis of 6,054 individuals from a prospective
population-based cohort, we studied potential associations
of thyrotropin and thyroid function parameters with all-
cause and cardiovascular mortality within the reference
ranges of normal thyrotropin and thyroid function. No
association was detected between thyrotropin and all-cause
mortality. Higher FT4 was associated with increased risk
of all-cause mortality and was stronger in females than in
males. Higher FT3 was associated with mortality in
females but not in males. Although we could not demon-
strate an association between thyrotropin and risk of car-
diovascular mortality in the total population, age-stratified
analyses unveiled a diverging trend toward increased risk
of cardiovascular mortality in younger participants and a
reduced risk in elderly with higher thyrotropin. Higher FT4
was strongly associated with increased cardiovascular
mortality in elderly, independent of traditional cardiovas-
cular risk factors, preexisting CVD, and abnormal thyroid
function tests.
Our results agree with accumulating evidence suggesting
that a high-normal thyroid function is associated with an
increased risk of mortality [5, 7, 8, 15, 16]. They extend
previous literature by demonstrating that variations within
the reference ranges of normal thyroid function increase the
risk of cardiovascular death in elderly individuals. This
finding reinforces the need for the revision of the current
reference ranges of thyrotropin and FT4 according to age
and sex and is in favor of an upward shift of thyrotropin and
a downward shift of FT4 reference ranges. This suggestion
is strongly corroborated by a recent study, which suggested
that the reference interval for thyrotropin should be shifted
upward in older men, whereas the reference interval for
FT4 should be compressed compared with conventional
reference ranges [23].
More than 90 years ago, Robertson was first to observe
reduced longevity in mice fed desiccated thyroid [24].
Subsequent research showed that hypothyroidism con-
siderably prolonged lifespan in Wistar rats compared with
their euthyroid counterparts [25], whereas a chronic state of
hyperthyroidism initiated at young age and maintained until
12 months of age shortened it [26]. Interestingly, if the state
of hyperthyroidism was initiated at young age and main-
tained until 22 months of age, there seemed to be little, if
any, additional adverse effect on lifespan, while initiation of
hyperthyroidism at 26 months of age was without effect on
further lifespan [27]. We found that the association of FT4
with mortality is modified by age, with strongest associa-
tions at higher age. Together, these observations provoke
the hypothesis that there is a difference between effects of
administered thyroid hormone and of endogenously syn-
thesized thyroid hormone on the process of ageing, and that
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beyond a certain age effects of endogenously synthesized
thyroid hormone may start to mimic that of administered
thyroid hormone. In this line of reasoning, it is of interest
that the dwarf mice strains Ames and Snell — which show
undetectable levels of thyrotropin, growth hormone, and
prolactin due to genetic mutations — have an extended
lifespan up to 70% and 50% compared with their wild-type
age-matched littermates, respectively [27]. This suggests
that overactivity of the thyroid gland could adversely affect
human longevity as well. Indeed, several studies on thyroid
dysfunction have demonstrated that low serum thyrotropin
and high FT4 are associated with decreased human long-
evity [12–15] and this effect appears to extend into the
high–normal range of thyroid function [5, 7, 8, 15, 16].
Recently, Bano et al. corroborated this finding by showing
that middle-aged and elderly individuals with low–normal
Table 2 Total and sex-stratified prospective associations of thyrotropin and thyroid function with all-cause and cardiovascular mortality
TSH FT4 FT3
HR (95% CI) P value Pinteraction
a HR (95% CI) P value Pinteraction
a HR (95% CI) P value Pinteraction
a
All-cause mortality
Total population
nevents/ntotal= 380/6054
Crude 0.93 (0.84–1.03) 0.18 1.29 (1.17–1.42) <0.001 0.88 (0.78–1.00) 0.05
Age- and sex-adjusted 0.99 (0.90–1.10) 0.89 0.90 1.24 (1.13–1.37) <0.001 0.03 0.99 (0.89–1.09) 0.81 0.002
Multivariable modelb 1.02 (0.92–1.14) 0.65 0.87 1.18 (1.07–1.30) 0.001 0.01 0.99 (0.89–1.10) 0.81 0.006
Men
nevents/ntotal= 288/3149
Crude 0.97 (0.85–1.09) 0.58 1.10 (0.99–1.24) 0.09 0.60 (0.51–0.70) <0.001
Age-adjusted 1.00 (0.89–1.13) 0.99 1.17 (1.04–1.31) 0.007 0.91 (0.78–1.07) 0.25
Multivariable modelc 1.00 (0.89–1.14) 0.95 1.14 (1.01–1.27) 0.03 0.92 (0.79–1.07) 0.27
Women
nevents/ntotal= 92/2905
Crude 1.00 (0.82–1.22) 0.99 1.68 (1.37–2.05) <0.001 1.11 (0.99–1.24) 0.08
Age-adjusted 0.99 (0.82–1.19) 0.89 1.56 (1.28–1.90) <0.001 1.18 (1.05–1.32) 0.005
Multivariable modelc 1.07 (0.89–1.30) 0.47 1.47 (1.19–1.82) <0.001 1.18 (1.02–1.35) 0.02
Cardiovascular mortality
Total population
nevents/ntotal= 103/6054
Crude 0.89 (0.73–1.09) 0.26 1.40 (1.16–1.69) <0.001 0.73 (0.57–0.93) 0.01
Age- and sex-adjusted 0.97 (0.79–1.18) 0.75 0.87 1.34 (1.11–1.61) 0.002 0.40 0.86 (0.66–1.12) 0.27 0.46
Multivariable modelb 0.98 (0.80–1.20) 0.86 0.84 1.23 (1.02–1.49) 0.03 0.22 0.91 (0.70–1.18) 0.48 0.67
Men
nevents/ntotal= 83/3149
Crude 0.92 (0.72–1.16) 0.48 1.21 (0.98–1.49) 0.07 0.50 (0.37–0.67) <0.001
Age-adjusted 0.96 (0.77–1.21) 0.73 1.29 (1.04–1.59) 0.02 0.83 (0.61–1.13) 0.27
Multivariable modelc 0.93 (0.73–1.18) 0.56 1.23 (1.00–1.52) 0.05 0.87 (0.64–1.18) 0.38
Women
nevents/ntotal= 20/2905
Crude 1.02 (0.67–1.55) 0.93 1.82 (1.19–2.78) 0.005 0.92 (0.53–1.61) 0.78
Age-adjusted 1.00 (0.67–1.50) 0.99 1.61 (1.07–2.42) 0.02 1.02 (0.59–1.76) 0.95
Multivariable modelc 1.17 (0.77–1.78) 0.47 1.46 (0.92–2.31) 0.10 0.96 (0.54–1.70) 0.89
Point estimates are expressed per SD increment in the predictor
CI confidence interval, FT3 free triiodothyronine, FT4 free thyroxine, HR hazard ratio, TSH thyrotropin
aEvidence against the null hypothesis of no effect modification by sex on the association of the thyroid function parameter and the specific outcome
concerned
bAdjusted for age, sex, current smoking, body-mass index, systolic blood pressure, use of antihypertensive drugs, total cholesterol/high-density
lipoprotein ratio, ln triglycerides, use of lipid-lowering drugs, type 2 diabetes, high-sensitive C-reactive protein, history of cardiovascular disease,
estimated glomerular filtration rate, and ln urinary albumin excretion
cAdjusted for all potential confounders except for sex
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thyroid function live up to 3.5 years longer than those with a
high–normal thyroid function [5].
The observation that high–normal thyroid function is
associated with all-cause and cardiovascular mortality in
advanced age suggests a subtle and cumulative effect of
higher FT4. The intrinsic liability of aerobic cellular
respiration to produce hazardous by-products, namely
reactive oxygen species (ROS), has prompted cells across
all domains of mammalian life to evolve intricate anti-
oxidant defense systems balancing the production and
clearance of ROS to preserve homeostasis [28]. Although
thyroid hormones greatly facilitate aerobic cellular respira-
tion by stimulating mitochondrial biogenesis and promoting
oxidative phosphorylation [29], paradoxically, they cause a
Table 3 Total and age-stratified prospective associations of thyrotropin and thyroid function with all-cause and cardiovascular mortality
TSH FT4 FT3
HR (95% CI) P value Pinteraction
a HR (95% CI) P value Pinteraction
a HR (95% CI) P value Pinteraction
a
All-cause mortality
Total population
nevents/ntotal= 380/6054
Crude 0.93 (0.84–1.03) 0.18 1.29 (1.17–1.42) <0.001 0.88 (0.78–1.00) 0.05
Age- and sex-adjusted 0.99 (0.90–1.10) 0.89 0.31 1.24 (1.13–1.37) <0.001 0.21 0.99 (0.89–1.09) 0.81 0.81
Multivariable modelb 1.02 (0.92–1.14) 0.65 0.55 1.18 (1.07–1.30) 0.001 0.46 0.99 (0.89–1.10) 0.81 0.85
Low age (<70 years)c
nevents/ntotal= 190/5304
Crude 0.86 (0.74–1.00) 0.05 1.16 (1.00–1.34) 0.05 1.00 (0.87–1.15) 0.98
Age- and sex-adjusted 0.89 (0.77–1.03) 0.13 1.15 (1.00–1.32) 0.05 0.99 (0.87–1.12) 0.82
Multivariable modelb 0.99 (0.85–1.15) 0.86 1.11 (0.97–1.28) 0.14 0.98 (0.86–1.12) 0.79
High age (≥70 years)c
nevents/ntotal= 190/750
Crude 1.04 (0.91–1.19) 0.57 1.35 (1.18–1.55) <0.001 1.06 (0.88–1.28) 0.55
Age- and sex-adjusted 1.10 (0.96–1.26) 0.18 1.36 (1.18–1.57) <0.001 1.02 (0.84–1.24) 0.85
Multivariable modelb 1.07 (0.93–1.24) 0.32 1.28 (1.11–1.48) 0.001 1.04 (0.86–1.25) 0.70
Cardiovascular mortality
Total population
nevents/ntotal= 103/6054
Crude 0.89 (0.73–1.09) 0.26 1.40 (1.16–1.69) 0.001 0.73 (0.57–0.93) 0.01
Age- and sex-adjusted 0.97 (0.79–1.18) 0.75 0.09 1.34 (1.11–1.61) 0.002 0.03 0.86 (0.66–1.12) 0.27 0.16
Multivariable modelb 0.98 (0.80–1.20) 0.86 0.04 1.23 (1.02–1.49) 0.03 0.06 0.91 (0.70–1.18) 0.48 0.28
Low age (<72 years)c
nevents/ntotal= 51/5551
Crude 1.07 (0.82–1.40) 0.62 1.16 (0.88–1.53) 0.28 0.98 (0.73–1.32) 0.90
Age- and sex-adjusted 1.11 (0.86–1.44) 0.42 1.13 (0.87–1.47) 0.35 0.98 (0.75–1.27) 0.87
Multivariable modelb 1.31 (1.00–1.72) 0.05 1.03 (0.78–1.34) 0.85 1.00 (0.77–1.30) 0.98
High age (≥72 years)c
nevents/ntotal= 52/503
Crude 0.80 (0.59–1.07) 0.13 1.55 (1.19–2.03) 0.001 0.77 (0.52–1.15) 0.20
Age- and sex-adjusted 0.82 (0.60–1.11) 0.20 1.63 (1.23–2.17) 0.001 0.72 (0.48–1.09) 0.12
Multivariable modelb 0.77 (0.56–1.06) 0.11 1.61 (1.19–2.18) 0.002 0.81 (0.54–1.21) 0.30
Point estimates are expressed per SD increment in the predictor
CI confidence interval, FT3 free triiodothyronine, FT4 free thyroxine, HR hazard ratio, TSH thyrotropin
aEvidence against the null hypothesis of no effect modification by age on the association of the thyroid function parameter and the specific outcome
concerned
bAdjusted for age, sex, current smoking, body-mass index, systolic blood pressure, use of antihypertensive drugs, total cholesterol/high-density
lipoprotein ratio, ln triglycerides, use of lipid-lowering drugs, type 2 diabetes, high-sensitive C-reactive protein, history of cardiovascular disease,
estimated glomerular filtration rate, and ln urinary albumin excretion
cCutoff values for the age strata were established through dichotomization of the cohort by the median age in participants who had succumbed, to
obtain an equal amount of events per stratum
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concomitant net decline of diverse components of the
antioxidant defense [30], promoting hyperthyroid indivi-
duals to shift into a state of oxidative stress. Indeed,
hyperthyroidism both increases ROS production and asso-
ciated damage to biological macromolecules [29, 30]. We
hypothesize that the observed age-related increased cardi-
ovascular mortality risk due to high–normal thyroid func-
tion is explained by the qualitative and quantitative decline
in antioxidant defense [31].
An inverse relationship between thyrotropin and FT4 is
anticipated based on the concept of negative feedback
regulation. This phenomenon was reflected by our results,
which showed that both low–normal thyrotropin and
high–normal FT4 levels were associated with increased risk
of cardiovascular death, with larger risk estimates for FT4
than for thyrotropin. Despite its consistency with previous
literature [5–7, 15], the latter finding is rather counter-
intuitive given that thyrotropin is deemed the most sensitive
marker for changes in thyroid function [32], because
pituitary secretion of thyrotropin is exquisitely sensitive to
minute fluctuations in FT4 [33]. However, it was recently
postulated that FT4 levels sensed by the pituitary gland as
appropriate could well be inappropriate for the cardiovas-
cular system [17] and potentially account for the observed
discrepancy between risk estimates.
Although T3 is the prime mediator of thyroid function in
cardiovascular physiology [10], we did not observe mean-
ingful associations between FT3 and all-cause or
Fig. 2 Graphical representation of the survival estimates of thyrotropin
and thyroxine for cardiovascular mortality stratified by age. a shows
the impact of thyrotropin on the risk of cardiovascular mortality in
participants younger than 72 years and b in participants aged 72 years
or older. c shows the impact of FT4 on the risk of cardiovascular
mortality in participants younger than 72 years and d in participants
aged 72 years or older. The lines represent the risk of cardiovascular
mortality. The areas about the lines represent the 95% confidence
interval associated with the line. The median thyrotropin and FT4
concentration was chosen as a reference in the upper two and lower
two panels, respectively. The distribution of thyrotropin and FT4 in
both age strata is depicted by the histogram in the background. Cutoff
values for the age strata were established through dichotomization of
the cohort by the median age in participants who had succumbed to
cardiovascular disease, to obtain an equal amount of events per stra-
tum. FT4 thyroxine, TSH thyrotropin
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cardiovascular mortality. Data on associations between FT3
and clinical outcomes within normal ranges of thyroid
function are scarce in the literature, complicating a reliable
comparison with findings from independent experts. One
multicentre, population-based cohort study examining
effects of total T3 concentrations on the incidence of atrial
fibrillation, coronary heart disease, heart failure, hip fracture,
dementia, and all-cause mortality did not detect any sig-
nificant association [6]. Another prospective cohort study
did not find any differences in cardiovascular parameters
according to quartiles of FT3 [16]. Possible explanations
could be inadequacy of serum FT3 concentrations as a sur-
rogate of tissue T3 concentrations or the short half-life of T3.
In this general population-based cohort study, with
available data on thyroid hormones, we quantified the
associations of thyrotropin and the thyroid function para-
meters FT4 and FT3 with incidence of all-cause and cardi-
ovascular mortality. We built on previous studies by
investigating potential effect modification by sex and age
and evaluated the influence of abnormal thyroid function
tests on these associations. We applied consistent metho-
dology throughout the analyses to diminish residual con-
founding and potential reverse causality and ascertained the
robustness of our findings by conducting an extensive range
of sensitivity analyses. A noteworthy strength was the size
of the study, the elaborate and complete follow-up, and the
wide range of the participants’ ages, allowing us to retain
statistical power while restricting the analyses, assess
potential time-dependent effects of thyrotropin and thyroid
function parameters on all-cause and cardiovascular mor-
tality across time, and investigate potential effect mod-
ification by age and sex.
Our samples had been stored for 14–17 years at −80 °C
and had not been thawed before. This time of storage before
assessment is comparable to that of other prospective stu-
dies, such as the Malmö Diet and Cancer study, wherein
samples had been stored for 14–19 years and were subjected
to two freeze-thaw cycles before measurements were per-
formed [34]. They also considered the validity of such
samples. It was first evaluated whether frozen samples differ
from fresh samples. This has been investigated by Männistö
et al. who found that, thyrotropin, FT4, and antithyroid
peroxidase levels were very similar when analyzed in frozen
versus fresh serum samples. For FT3, however, levels were
slightly higher in frozen/thawed samples as compared with
fresh serum samples [35]. Concerning storage time, the
same authors reported that thyrotropin, FT4, and FT3 levels
were not affected by storage for 14–18 years, but antithyr-
oid peroxidase levels were only stable for up to 14 years,
following which they displayed a slight increase [36]. Thus,
freezing/thawing and storage time may have affected the
absolute levels of FT3 and antithyroid peroxidase in our
study, but there is nothing to suggest that effects of freezing/
thawing and storage time on samples differed between
subjects that developed an event and subjects that did not
develop an event, making it unlikely that relative compar-
isons such as risk estimates could have been affected. The
evaluation of thyrotropin and thyroid function parameters
was based on a single measurement and within-person
variation may therefore be a potential source for measure-
ment error. In many instances, hormonal measurements
were done more than a decade before the study outcomes,
so it was not really known what the thyroid status of study
participants were at the time of the events. Importantly, due
to the phenomenon of regression dilution bias, the asso-
ciation between variables assessed at one time point — like
thyroid function tests in this case — and prospective
development of events, is underestimated [37]. Indeed, if
we would have had data of repeated measurements on
thyroid function tests, this would likely have resulted in
strengthening of associations to be found, like previously
has been shown for thyrotropin and FT4 [37]. In addition,
our study almost exclusively included Caucasians, requiring
verification of our findings in other populations. Lastly,
because of the observational nature of our study, we cannot
conclude that positive associations between high–normal
thyroid function and cardiovascular mortality in elderly
reflect cause and effect relations nor can we entirely elim-
inate the possibility of residual confounding.
In conclusion, the findings from this prospective cohort
study showed that elderly individuals from the general
population with a high–normal FT4 are at increased risk of
all-cause and cardiovascular death and emphasize the need
of redefining the current reference ranges of thyroid func-
tion according to age and sex. Further studies are warranted
to replicate our findings and shed light on the mechanistic
basis for the differences in cardiovascular mortality risk
within reference ranges of normal thyroid function.
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